Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials
- 1 August 2019
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (8) , 1440-1446
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- National Breast Cancer Foundation (PF-17-007)
- AstraZeneca
- Cancer Council NSW
- Roche
- Cancer Council Tasmania
- Merck Sharp and Dohme United Kingdom
- Bristol-Myers Squibb
- Cancer Council South Australia
- Government of South Australia
This publication has 17 references indexed in Scilit:
- Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markersBritish Journal of Cancer, 2017
- Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)Journal of Clinical Oncology, 2017
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialThe Lancet, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialThe Lancet, 2016
- A Laboratory Prognostic Index Model for Patients with Advanced Non-Small Cell Lung CancerPLOS ONE, 2014
- Data Sharing, Year 1 — Access to Data from Industry-Sponsored Clinical TrialsNew England Journal of Medicine, 2014
- Interpreting the clinical utility of a pharmacogenomic marker based on observational association studiesThe Pharmacogenomics Journal, 2013
- Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03European Journal of Cancer, 2009
- MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORSStatistics in Medicine, 1996